21st Century Cures: “…has the makings of something groundbreaking…the entire health care community should be paying attention.”
As another hearing approaches next week, the 21st Century Cures Initiative continues to garner enthusiastic support. An op-ed published in The Morning Consult praises the committee’s bipartisan successes under the leadership of Chairman Fred Upton (R-MI) and expresses hope for the future of the 21st Century Cures initiative. Jeffrey Kimbell and Kenneth L. Hodge write, “Along the way, Chairman Upton has made it known that nothing is off limits, and no idea is too big or too small. … the life-science community has a unique opportunity with Chairman Upton and Diana DeGette’s 21st Century Cures Initiative to meaningfully impact the regulatory environment for future product development that meets the needs of patients today and tomorrow.” Join the #Path2Cures initiative on Facebook and Twitter and learn more here.
June 5, 2014
Life Sciences: A New Opportunity for Innovation
When most people hear that Congress is working on health care legislation, they immediately assume we are in for another politically charged and polarizing debate. However, history shows that when it comes to improving the ability of our nation’s pharmaceutical and medical device manufacturers to bring safe and innovative products to patients, Congress can come together and work in a bipartisan fashion to craft meaningful legislation. …
Now, Chairman Upton has partnered with Congresswoman Diana DeGette (D-CO) to provide a new opportunity for public and private stakeholders, in an effort to improve the health of people worldwide, to participate in an effort to shape the future of the regulatory ecosystem in which they exist.
On April 30, 2014 Upton and DeGette announced the “21st Century Cures” initiative, which will focus on three key areas to help advance the pace of medical innovation in the United States: discovery, development, and delivery. By examining these areas, Upton and the Committee hope to bring this country’s technological advances to bear on the regulatory frameworks impacting innovation in the life-sciences sector. …
We can expect the Committee to continue this robust, public discussion through more hearings and roundtables this summer and fall. In addition, they have already released three white papers outlining their ideas on specific issues and I expect more to come – each one presenting stakeholders an opportunity to publicly comment on these ideas. Along the way, Chairman Upton has made it known that nothing is off limits, and no idea is too big or too small.
In conclusion, the life-science community has a unique opportunity with Chairman Upton and Diana DeGette’s 21st Century Cures Initiative to meaningfully impact the regulatory environment for future product development that meets the needs of patients today and tomorrow. This initiative has the makings of something groundbreaking, and given Chairman Upton and the Energy & Commerce Committee’s track record of tackling big problems, the entire health care community should be paying attention.
Read the complete piece online HERE.